C57BL/6JCya-Rev3lem1flox/Cya
Common Name:
Rev3l-flox
Product ID:
S-CKO-04779
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Rev3l-flox
Strain ID
CKOCMP-19714-Rev3l-B6J-VA
Gene Name
Product ID
S-CKO-04779
Gene Alias
Rev; Rev3; Sez4
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
10
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Rev3lem1flox/Cya mice (Catalog S-CKO-04779) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000019986
NCBI RefSeq
NM_011264
Target Region
Exon 2
Size of Effective Region
~1.3 kb
Detailed Document
Overview of Gene Research
REV3L, also known as Protein reversion less 3-like, encodes the catalytic subunit of error-prone translesion synthesis polymerase zeta. It is involved in DNA damage repair pathways, specifically translesion DNA synthesis (TLS), which allows DNA replication to proceed past damaged sites. This function is crucial for maintaining genome stability, but its error-prone nature can also lead to mutagenesis, making it relevant in cancer research [1,2,3,4,5,6,8].
In various cancers, REV3L has shown significant associations. In the Jammu and Kashmir population, certain REV3L single nucleotide variants (rs1002481, rs462779, rs465646) were strongly associated with an increased risk of non-small cell lung cancer (NSCLC) [1]. In NSCLC cell lines, cisplatin treatment induced REV3L expression, and overexpression of REV3L conferred cisplatin resistance, while knockdown sensitized the cells to cisplatin, suggesting it could be a novel target for NSCLC chemotherapy [2]. Similar findings were seen in esophageal squamous cell carcinoma, where REV3L was upregulated, and its downregulation decreased cell proliferation, invasive capacity, and increased chemosensitivity to 5-fluorouracil [3]. In gliomas, REV3L was overexpressed, and its downregulation using RNA interference enhanced cisplatin sensitivity [5]. In cervical cancer, the expression of REV3L was higher in cancer tissues, and its suppression or overexpression affected cell proliferation, colony formation, and cisplatin sensitivity [6]. Also, in a myelodysplastic syndrome patient, a REV3L mutation (c.9253-6T>C) was associated with poor prognosis [7]. In a Chinese population, the rs465646 polymorphism in REV3L was associated with lung cancer susceptibility [8]. In NSCLC, circular RNA PRMT5 promoted cisplatin resistance via the miR-4458/REV3L axis [9].
In conclusion, REV3L is essential for translesion DNA synthesis, playing a significant role in maintaining genome stability. Its dysregulation is associated with various cancers, including NSCLC, esophageal, glioma, cervical, and myelodysplastic syndromes. Understanding REV3L's function and its associated genetic variations can potentially lead to new diagnostic and therapeutic strategies for these diseases.
References：
1. Jamwal, Rajeshwer Singh, Mahajan, Nikita, Bhat, Gh Rasool, Kumar, Rakesh, Bhat, Audesh. 2021. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir. In Cancer epidemiology, 75, 102047. doi:10.1016/j.canep.2021.102047. https://pubmed.ncbi.nlm.nih.gov/34655923/
2. Wang, Wenjie, Sheng, Wenjiong, Yu, Chenxiao, Zhang, Huojun, Zhang, Shuyu. 2015. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. In Oncology reports, 34, 1460-8. doi:10.3892/or.2015.4121. https://pubmed.ncbi.nlm.nih.gov/26165320/
3. Zhu, Xiaozhong, Zou, Shitao, Zhou, Jundong, Wu, Jinchang, Chen, Yihong. 2016. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma. In Oncology reports, 35, 1664-70. doi:10.3892/or.2016.4549. https://pubmed.ncbi.nlm.nih.gov/26752104/
4. Halas, Agnieszka, Fijak-Moskal, Jolanta, Kuberska, Renata, Sledziewska-Gojska, Ewa, Płoski, Rafał. 2021. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant. In Journal of molecular medicine (Berlin, Germany), 99, 415-423. doi:10.1007/s00109-020-02033-3. https://pubmed.ncbi.nlm.nih.gov/33474647/
5. Wang, Huibo, Zhang, Shu-Yu, Wang, Shuai, Lu, Daru, Zhao, Shiguang. . REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. In Neuro-oncology, 11, 790-802. doi:10.1215/15228517-2009-015. https://pubmed.ncbi.nlm.nih.gov/19289490/
6. Yang, Li, Shi, Tingyan, Liu, Fei, Yang, Gong, Cheng, Xi. 2015. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. In PloS one, 10, e0120334. doi:10.1371/journal.pone.0120334. https://pubmed.ncbi.nlm.nih.gov/25781640/
7. Oliveira, Roberta Taiane G de, França, Ivo Gabriel F, Junior, Howard L R, Magalhães, Silvia M M, Pinheiro, Ronald F. 2020. c.9253-6T>c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome. In Hematology, transfusion and cell therapy, 43, 377-381. doi:10.1016/j.htct.2020.05.006. https://pubmed.ncbi.nlm.nih.gov/32682781/
8. Zhang, S, Chen, H, Zhao, X, Wei, Q, Lu, D. 2012. REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. In Oncogene, 32, 242-50. doi:10.1038/onc.2012.32. https://pubmed.ncbi.nlm.nih.gov/22349819/
9. Pang, Jun, Ye, Liwen, Zhao, Dan, Zhao, Ding, Chen, Qingwei. 2020. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer. In Cell biology international, 44, 2416-2426. doi:10.1002/cbin.11449. https://pubmed.ncbi.nlm.nih.gov/32808744/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen